SCHEMBL7136108

SCHEMBL7136108

CN(Cc1ccccc1)C(=O)[C@@H]1C[C@@H](SS[C@@H]2C[C@@H](C(=O)N(C)Cc3ccccc3)N(S(=O)(=O)c3ccc4ccccc4c3)C2)CN1S(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
KDM4E B2RXH2 1/20 0.50
MME P08473 2/20 0.49
ACE P12821 2/20 0.49
ECE1 P42892 2/20 0.49
CCR4 P51679 5/20 0.49
MMP1 P03956 1/20 0.43
MMP3 P08254 1/20 0.43
MMP13 P45452 1/20 0.43
AKR1C3 P42330 2/20 0.41
PKM P14618 1/20 0.41
POLB P06746 1/20 0.41
AKR1C1 Q04828 1/20 0.41
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
CPT2 P23786 1/20 0.40
CPT1A P50416 1/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7135953 0.87 ECE1 (0.63) ALDH1A1KDM4EMMEACEECE1
SCHEMBL7135937 0.87 ECE1 (0.63) ALDH1A1KDM4EMMEACEECE1
SCHEMBL7134758 0.87 ECE1 (0.63) ALDH1A1KDM4EMMEACEECE1
SCHEMBL7135712 0.87 ECE1 (0.53) ALDH1A1KDM4EMMEACEECE1
SCHEMBL7138285 0.82 AKR1C3 (0.52) ALDH1A1KDM4EMMEACEECE1
SCHEMBL7141900 0.82 AKR1C3 (0.52) ALDH1A1KDM4EMMEACEECE1
SCHEMBL7140077 0.82 ECE1 (0.49) ALDH1A1KDM4EMMEACEECE1
SCHEMBL7137883 0.81 ECE1 (0.47) ALDH1A1KDM4EMMEACEECE1
SCHEMBL5723306 0.79 ECE1 (0.58) ALDH1A1KDM4EMMEACEECE1
SCHEMBL7148868 0.79 MME (0.47) ALDH1A1KDM4EMMEACEECE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303485-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed
WO-2002006222-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP ALDH1A1 767/4885KDM4E 1295/4885MME 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.